ReviewComputational and structural biotechnology journal2025
Unlocking TRPM7 interactions: A database-driven quest.
Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Interaction between the Tyrosine Kinase Receptor EphA2 and RNF5: Structural Insights from anComputational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient receptor potential cation channel subfamily M member 7 (TRPM7) is a dual function protein comprising a non-selective cation channel and an atypical kinase domain. TRPM7 has been involved in many diseases including malignancies. Indeed, TRPM7 is proposed as a promising target for therapeutical drug design. Numerous studies have shown that TRPM7 interacts with proteins involved in regulating intracellular signaling. Therefore, a better understanding of the TRPM7 interactome would provide insight into pathophysiological mechanisms at the cellular and molecular levels. It could also open up new therapeutic avenues for molecules targeting either the proteins of interest directly or protein-protein interactions. In the first part of this work, we present the interaction partners described in the literature for TRPM7 and their potential impacts on cell biology. In the second part of the manuscript, we use public databases and protein interaction modeling tools to characterize the TRPM7 interactome. In particular, the analysis of the TRPM7 interactome using experimental data (BioGRID) and modeling tools (ProteinPrompt) has allowed us to isolate 19 genes of interest mainly related to small GTPase pathways involved in digestive neoplasia such as colorectal and pancreatic cancers. In summary, we provide an extended overview of potential TRPM7 interactors which need to be validated in cellular models. This will provide crucial insights into the molecular mechanisms at the tumor cell membrane, helping us to propose new therapeutic targets for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.